There were a lot of outliers in the US market for drug developer initial public offerings in 2018, including the biggest-ever biopharmaceutical IPO, but on average the returns on these investments were negative by the end of the year.
While 67 biopharma companies managed to launch IPOs in the US in 2018, 41 of these firms were trading below...






